OSLO,
Norway, Aug. 4, 2022 /PRNewswire/ -- Navamedic has
signed an agreement with the French pharmaceutical company Vectans
Pharma, which gives Navamedic the exclusive right to market and
sell an innovative and unique muco-adhesive buccal tablet for
single-dose treatment of cold sores (herpes labialis) in the Nordic
and Benelux regions. This entitles Navamedic to the ownership of
the marketing authorizations for the product in these regions.
"This acquisition is a great example of how we can utilize our
strong presence and in-depth competence in our markets to broaden
our portfolio through partnerships with international pharma
companies and introduce attractive products to the benefit of
end-users. It is a key element of our value creation strategy to
secure and increase value creation through ownership of products
and exclusive marketing rights," says Kathrine Gamborg Andreassen, CEO of Navamedic
ASA.
The product is currently marketed as a prescription drug in the
US and South Korea but is now in
transition to becoming a non-prescription or "Over the Counter
(OTC)" drug in many markets. It has already been approved as OTC
drug in France and Italy and applications are currently in
progress in many European countries.
Cold sores - also called fever blisters - is a common and
recurring condition that affects about 20 - 40% of the population.
It is caused by the herpes simplex virus and the outbreaks are
often triggered by another illness, sunshine exposure, or menstrual
periods. During outbreaks, the sores are contagious from the first
moment of tingling and can spread from person to person by close
contact.
The transfer of the marketing authorizations will take place
subsequent to the OTC approval in each country. Navamedic expects
the first commercial sale in the Nordics and Benelux to take place
in the first half of 2024.
"We are delighted to collaborate with Navamedic and to initiate
our partnership together. We firmly believe that Sitavig® has the
potential to become the `best-in-disease' medicine for cold sores
in the Nordic and Benelux regions, offering a new innovative
treatment to patients in need. This partnership is an important
step in our development plan and reinforces our international
strategy," says Jérôme Théron, co-founder and CEO of Vectans
Pharma.
About Sitavig®:
Sitavig® (acyclovir) is a 50mg Muco-Adhesive Buccal tablet that
represents a breakthrough in the treatment of cold sores. Sitavig®
is a unique single-dose treatment that is placed under the
patient's lip and works by delivering a concentrated dose of
acyclovir that stays localized at the site of viral replication in
the mouth.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO,
Navamedic
Mobile: +47 951 78680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62842
E-mail: lars.hjarrand@navamedic.com
About Navamedic ASA:
Navamedic ASA is a Nordic pharma company and reliable provider
of high-quality products, delivered to hospitals and through
pharmacies, meeting the specific needs of patients and consumers by
leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in
all the Nordic countries, the Baltics and Benelux, with sales
representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA).
For more information, please visit www.navamedic.com
About Vectans Pharma:
"Vectans Pharma is a French pharmaceutical company with an
international reach, specialized in the development of
muco-adhesive drugs, and offering new therapeutic perspectives to
the pharmaceutical industry. Thanks to its innovative platform,
Lauriad®, our company ensures the development of new drugs and,
with its international partners, the commercialization of Sitavig®
and Loramyc® worldwide. Vectans Pharma delivers life-changing
treatments, respectful of both humans and the environment, that
improve patient access and experience around the world."
For more information about Vectans Pharma, please visit
https://www.vectanspharma.com/
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa---exclusive-agreement-with-vectans-pharma-for-the-unique-cold-sore-treatment-product-s,c3610318
